MACHINE LEARNING TECHNIQUES FOR AUTOMATIC EVALUATION OF CLINICAL TRIAL DATA

    公开(公告)号:US20220375560A1

    公开(公告)日:2022-11-24

    申请号:US17882824

    申请日:2022-08-08

    Applicant: IQVIA Inc.

    Abstract: Aspects of the subject matter described in this specification are embodied in systems and methods that utilize machine-learning techniques to evaluate clinical trial data using one or more learning models trained to identify anomalies representing adverse events associated with a clinical trial investigation. In some implementations, investigation data collected at a clinical trial site is obtained. A set of models corresponding to the clinical trial site is selected. Each model included in the set of models is trained to identify, based on historical investigation data collected at the clinical trial site, a distinct set of one or more indicators that indicate a compliance risk associated with the investigation data. A score for the clinical trial site is determined based on the investigation data relative to the historical investigation data. The score represents a likelihood that the investigation data is associated with at least one indicator representing the compliance risk.

    SOURCE DATA REVIEW SYSTEM
    2.
    发明申请

    公开(公告)号:US20250087372A1

    公开(公告)日:2025-03-13

    申请号:US18883806

    申请日:2024-09-12

    Applicant: IQVIA Inc.

    Abstract: Methods, systems, and apparatus, including computer programs encoded on computer storage media, for source data review and document compliance. The computer obtains a plurality of source documents, each source document comprising clinical trial information of the one or more clinical studies. The computer identifies, for each source document and by a natural language processing (NLP) model, a plurality of entities of the one or more clinical studies from the information related to the participants of the one or more clinical studies in the source document. The computer generates an updated NLP models configured to detect one or more events likely to have occurred among the plurality of entities, each event being associated with at least one entity from the plurality of entities. The updated NLP model is configured to update parameters in response to receiving a user input representing feedback to a model output from the updated NLP model.

    MACHINE LEARNING TECHNIQUES FOR AUTOMATIC EVALUATION OF CLINICAL TRIAL DATA

    公开(公告)号:US20250124529A1

    公开(公告)日:2025-04-17

    申请号:US18989609

    申请日:2024-12-20

    Applicant: IQVIA Inc.

    Abstract: Aspects of the subject matter described in this specification are embodied in systems and methods that utilize machine-learning techniques to evaluate clinical trial data using one or more learning models trained to identify anomalies representing adverse events associated with a clinical trial investigation. In some implementations, investigation data collected at a clinical trial site is obtained. A set of models corresponding to the clinical trial site is selected. Each model included in the set of models is trained to identify, based on historical investigation data collected at the clinical trial site, a distinct set of one or more indicators that indicate a compliance risk associated with the investigation data. A score for the clinical trial site is determined based on the investigation data relative to the historical investigation data. The score represents a likelihood that the investigation data is associated with at least one indicator representing the compliance risk.

    Machine learning techniques for automatic evaluation of clinical trial data

    公开(公告)号:US11526953B2

    公开(公告)日:2022-12-13

    申请号:US16451097

    申请日:2019-06-25

    Applicant: IQVIA Inc.

    Abstract: Aspects of the subject matter described in this specification are embodied in systems and methods that utilize machine-learning techniques to evaluate clinical trial data using one or more learning models trained to identify anomalies representing adverse events associated with a clinical trial investigation. In some implementations, investigation data collected at a clinical trial site is obtained. A set of models corresponding to the clinical trial site is selected. Each model included in the set of models is trained to identify, based on historical investigation data collected at the clinical trial site, a distinct set of one or more indicators that indicate a compliance risk associated with the investigation data. A score for the clinical trial site is determined based on the investigation data relative to the historical investigation data. The score represents a likelihood that the investigation data is associated with at least one indicator representing the compliance risk.

    CLINICAL TRIAL OPERATIONAL PLAN GENERATION

    公开(公告)号:US20250087315A1

    公开(公告)日:2025-03-13

    申请号:US18885234

    申请日:2024-09-13

    Applicant: IQVIA Inc.

    Abstract: Methods, systems, and apparatus, including computer programs encoded on computer storage media, for generating operational plans. The method includes grounding a natural language processing (NLP) model in clinical trial context documents containing information related to execution of clinical trials; receiving a request to generate a clinical trial operational plan; by the NLP model and responsive to the received request, generating the clinical trial operational plan such that the generated plan includes content based on the clinical trial context documents; providing the generated clinical trial operational plan as an output; receiving revisions to the generated clinical trial operational plan, wherein the revisions applied to the generated clinical trial operational plan correspond to a revised clinical trial operational plan; and grounding the NLP model in the revised clinical trial operational plan.

    AI AND ML ASSISTED SYSTEM FOR DETERMINING SITE COMPLIANCE USING SITE VISIT REPORT

    公开(公告)号:US20220359048A1

    公开(公告)日:2022-11-10

    申请号:US17308415

    申请日:2021-05-05

    Applicant: IQVIA Inc.

    Abstract: Methods and systems to automatically construct a clinical study site visit report (SVR), conduct the SVR, evaluate the SVR in real-time, and provide feedback while the SVR is being conducted. Responses to the SVR include user-selectable answers and natural language notes. Each response is evaluated as it is submitted based on a combination of pre-configured rules and a computer-trained model. If an anomaly is detected and is not already captured in the SVR, an alert is generated during performance of the SVR. The alert may include recommended remedial action.

Patent Agency Ranking